Biomarkers and echocardiography data
| Variable | Visit 1 | Visit 2 | N | p-value | Visit 3 | N | p-value |
|---|---|---|---|---|---|---|---|
| usTnT – pg/ml | 11.4 ± 5.4 | 10.9 ± 5.1 | 19 | 0.93 | 8.3 ±3.2 | 8 | 1 |
| >30% increase in usTnT from Visit 1 – no. (%) | 3 (15.8) | 19 | 1 | 2 (25) | 8 | 1 | |
| NT-proBNP – pg/ml | 266 ± 250 | 258 ± 378 | 17 | 0.55 | 226 ± 430 | 8 | 0.60 |
| >30% increase in NT-proBNP from Visit 1 – no. (%) | 6 (35.3) | 17 | 1 | 2 (25) | 8 | 1 | |
| LVEF – % | 68 ± 8 | 67 ± 8 | 22 | 0.66 | 69 ± 9 | 16 | 0.63 |
| >30% increase in LVEF from Visit 1 – no. (%) | 0 (0) | 22 | 1 | 1 (6) | 16 | 1 | |
| Diastolic dysfunction – no. (%) | 9 (27.3) | 6 (27.3) | 21 | 1 | 4 (23.5) | 17 | 1 |
P values for univariate logistic regression models for cardiotoxicity
| Independent variable | OR (95% CI) | p-value |
|---|---|---|
| Age in years | 1.044 (0.955–1.142) | 0.34 |
| Male sex | 0.824 (0.198–3.432) | 0.79 |
| Metastatic disease | 0.765 (0.182–3.210) | 0.71 |
| History of ischemic heart disease | 12.857 (1.157–142.880) | 0.04 |
| History of arterial hypertension | 1.583 (0.377–6.649) | 0.53 |
| Glomerular filtration rate at Visit 1 | 1.000 (0.972–1.029) | 1.00 |
| No. of chemotherapy cycles | 0.931 (0.474–1.827) | 0.83 |
| usTnT in pg/ml at Visit 1 | 0.961 (0.823–1.122) | 0.62 |
| NT-proBNP in pg/ml at Visit 1 | 1.000 (0.997–1.003) | 0.93 |
| LVEF in % at Visit 1 | 1.356 (0.000–37889.6) | 0.95 |
Multivariate regression model for cardiotoxicity
| Independent variable | OR (95% CI) | p-value |
|---|---|---|
| Age in years | 1.044 (0.955 – 1.142) | 0.52 |
| Male sex | 0.824 (0.198 – 3.432) | 0.21 |
| History of ischemic heart disease | 12.857 (1.157 – 142.880) | 0.026 |
| LVEF in % at Visit 1 | 1.356 (0.000 – 37889.6) | 0.92 |
Patients’ characteristics
| Age – yr | 61 ± 9 |
|---|---|
| Male sex – no. (%) | 22 (54) |
| Arterial hypertension – no. (%) | 17 (41) |
| Ischemic heart disease – no. (%) Cardiovascular disease – no. (%) | 4 (10) 5 (12) |
| Glomerular filtration rate – ml/min/1.73 m2 | 102 ± 28 |
| Advanced disease – no. (%) | 28 (68) |
Chemotherapy treatment characteristics
| Chemotherapy cycles – median (range) | 4 (2-6) |
|---|---|
| Chemotherapy – no. (%) | |
| Cisplatin | 28 (68) |
| Carboplatin | 8 (20) |
| Both, in sequence | 5 (12) |
| and | |
| Vinorelbine | 11 (27) |
| Pemetrexed | 22 (54) |
| Gemcitabine | 8 (19) |